SILO Silo Pharma: יחס מחיר להכנסות חזויות

Silo Pharma, Inc. (SILO) relies on investments as it lacks a stable cash flow. The projected P/S level on the GURU.Markets terminal chart visualizes this imbalance, where 58.90 reflects the latest metric value. While the nasal drug SPC-15 for PTSD offers growth prospects, strict DEA oversight and the risk of failed trials create significant barriers for the biotech firm.

Silo Pharma, Inc. (SILO) is developing innovative therapies for neurodegenerative pathologies based on psilocybin formulations. By analyzing the company's P/S expectations, an investor assesses market capitalization relative to projected revenue, which allows them to filter out speculative noise and determine a fair discount for future cash flows from clinical trials, thereby confirming the long-term fundamental stability of the business.